Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in France-Reference-Cited by-同舟云学术

Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in France

Published:2023-01-05 Issue:2 Volume:23 Page:205-213
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Oppe Mark¹,Muresan Bogdan²,Chan Katie³,Radu Xenia³,Schultz Bob G.⁴^ORCID,Turpin Robin S.⁵,Nucit Arnaud⁶,Fenu Elisabetta⁷

Affiliation:

1. Axentiva Solutions, Barcelona, Spain

2. IQVIA, Health Economics and Outcomes Research, Amsterdam, Netherlands

3. IQVIA, EMEA HE Real-World Methods & Evidence Generation, London, UK

4. Takeda Pharmaceuticals U.S.A., Inc, US Medical Affairs, Value & Evidence Generation, Lexington, MA, USA

5. Takeda Pharmaceuticals U.S.A., Inc, US Value Evidence, Bannockburn, IL, USA

6. Takeda France S.A.S, Health Economics - Patient Value & Access, Paris, France

7. Takeda Pharmaceuticals International AG, Global Health Economics, Zurich, Switzerland

Funder

This work was financially supported by Takeda. Medical writing support was provided by Milena Wagner, PhD, of Excel Medical Affairs and funded by Takeda

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2023.2160322

Reference38 articles.

1. A comprehensive review and update on ulcerative colitis,

2. Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA) patient survey

3. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

4. Geographical variations of inflammatory bowel disease in France: A study based on national health insurance data

5. The changing pattern of Crohn’s disease incidence in northern France: a continuing increase in the 10- to 19-year-old age bracket (1988-2007)

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Take vedolizumab home: transition from intravenous to subcutaneous treatment;Therapeutic Advances in Chronic Disease;2024-01

2. Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study;Crohn's & Colitis 360;2024-01-01

3. Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission;Journal of Gastrointestinal and Liver Diseases;2023-12-22

4. Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses;Scandinavian Journal of Gastroenterology;2023-11-25

5. Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model;Expert Review of Pharmacoeconomics & Outcomes Research;2023-10-17